NYC’s safe injection sites claim ‘significant success’ despite spike in overdoses, report says

The nonprofit operating the controversial facilities doesn't track outcomes for patients experiencing cardiac arrest, strokes ...

HYMPAVZI(R) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...
TipRanks on MSN

Pfizer presents results from the Phase 3 BASIS study on HYMPAVZI

Pfizer (PFE) presented results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with ...

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

At least 46 people rushed to hospital from NYC’s 2 overdose prevention centers, who says it doesn’t know what happened to them

New York City’s two government-funded shooting galleries are supposed to prevent fatal overdoses — but at least 46 clients ...
The Mirror US on MSN

At least 46 people rushed to hospital from NYC’s 2 overdose prevention centers

At least 46 people from the two New York City safe-injection sites were rushed to the hospital in cardiac arrest or with life ...